Truist Financial Forecasts Strong Price Appreciation for Teva Pharmaceutical Industries (NYSE:TEVA) Stock

Teva Pharmaceutical Industries (NYSE:TEVA) had its target price lifted by analysts at Truist Financial from $38.00 to $42.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Truist Financial’s price objective indicates a potential upside of 22.26% from the company’s current price.

A number of other analysts also recently issued reports on the company. Barclays lifted their price target on Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the stock an “overweight” rating in a report on Friday, January 30th. Piper Sandler boosted their target price on Teva Pharmaceutical Industries from $30.00 to $40.00 and gave the stock an “overweight” rating in a research note on Monday, December 22nd. The Goldman Sachs Group upped their price target on Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the company a “buy” rating in a report on Monday, February 9th. Bank of America raised their price objective on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. Finally, Scotiabank boosted their price objective on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock a “sector outperform” rating in a research report on Thursday, January 29th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $37.56.

Teva Pharmaceutical Industries Stock Performance

NYSE TEVA opened at $34.35 on Wednesday. The stock has a market capitalization of $39.50 billion, a price-to-earnings ratio of 28.63, a PEG ratio of 11.42 and a beta of 0.70. The stock has a 50-day moving average of $32.49 and a 200 day moving average of $24.94. The company has a current ratio of 1.04, a quick ratio of 0.80 and a debt-to-equity ratio of 1.89. Teva Pharmaceutical Industries has a twelve month low of $12.47 and a twelve month high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share for the quarter, topping analysts’ consensus estimates of $0.65 by $0.31. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The firm had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.36 billion. During the same period in the previous year, the business posted $0.71 earnings per share. Teva Pharmaceutical Industries’s quarterly revenue was up 11.4% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Sell-side analysts anticipate that Teva Pharmaceutical Industries will post 2.5 EPS for the current fiscal year.

Insider Activity at Teva Pharmaceutical Industries

In other news, Director Roberto Mignone sold 77,400 shares of the business’s stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $30.24, for a total transaction of $2,340,576.00. Following the completion of the sale, the director owned 367,600 shares in the company, valued at approximately $11,116,224. The trade was a 17.39% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Mark Sabag sold 216,892 shares of the stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $28.73, for a total value of $6,231,307.16. Following the completion of the sale, the insider owned 52,828 shares of the company’s stock, valued at approximately $1,517,748.44. This trade represents a 80.41% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 422,060 shares of company stock valued at $12,254,965 over the last quarter. 0.49% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Large investors have recently made changes to their positions in the company. Compound Planning Inc. acquired a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter valued at about $323,000. Invesco Ltd. raised its stake in Teva Pharmaceutical Industries by 4.8% during the 4th quarter. Invesco Ltd. now owns 2,710,105 shares of the company’s stock valued at $84,582,000 after purchasing an additional 124,304 shares during the last quarter. Corient Private Wealth LLC lifted its stake in shares of Teva Pharmaceutical Industries by 30.4% in the fourth quarter. Corient Private Wealth LLC now owns 49,848 shares of the company’s stock valued at $1,520,000 after buying an additional 11,628 shares during the period. Alpine Woods Capital Investors LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth approximately $463,000. Finally, Mercer Global Advisors Inc. ADV raised its stake in shares of Teva Pharmaceutical Industries by 5.6% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 72,747 shares of the company’s stock valued at $2,270,000 after buying an additional 3,874 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.